≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Chronic myeloid leukaemia

DOID Endpoint Browser

C3_CML

obsolete_chronic myeloid leukemia: ['Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.']

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cause of death: ICD-10 — C92.1
  • Cause of death: ICD-9 — 2051A
  • Cause of death: ICD-8 — 20515
  • Cancer registry: Topography ICD-O-3 — ANY
  • Cancer registry: Morphology ICD-O-3 — 9863|9875
  • Cancer registry: Behaviour codes — 3

2 out of 7 registries used, show all original rules.

314

4. Check minimum number of events

None

314

5. Include endpoints

None

314

6. Filter based on genotype QC (FinnGen only)

175

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF8

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 175 77 98
Unadjusted period prevalence (%) 0.04 0.03 0.04
Median age at first event (years) 60.98 57.56 63.66

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
182
Matched controls
1820
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
254.4
179
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
16384.0
237.3
173
*
XW000
NOMESCO Finland
Bone marrow biopsy
164.5
200.5
102
14
9863/3-C42.1
ICD-O-3
Chronic myeloid leukemia, NOS, of bone marrow
+∞
199.7
153
*
189
Kela drug reimbursment
Imatinib
+∞
150.7
123
*
L01XE01
ATC
[U] imatinib
+∞
115.2
98
*
M04AA01
ATC
allopurinol; systemic
23.0
106.8
124
155
L01EA01
ATC
imatinib; oral
+∞
89.0
78
*
L01XX05
ATC
hydroxycarbamide; oral
1092.6
76.0
69
*
316
Kela drug reimbursment
Imatinib
+∞
71.7
64
*
152
Kela drug reimbursment
Nilotinib
+∞
41.2
38
*
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
+∞
39.0
36
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
127.3
38.5
40
*
L01XX28
ATC
[U] imatinib
+∞
35.6
33
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.7
33.5
58
104
150
Kela drug reimbursment
Dasatinib
+∞
30.0
28
*
L01XE08
ATC
[U] nilotinib
+∞
28.9
27
*
L03AA02
ATC
filgrastim; parenteral
+∞
28.9
27
*
9875/3-C42.1
ICD-O-3
Chronic myelogenous leukemia, BCR/ABL positive of bone marrow
+∞
28.9
27
*
328
Kela drug reimbursment
Nilotinib
+∞
27.8
26
*
L01EA03
ATC
nilotinib; oral
+∞
25.6
24
*
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
+∞
25.6
24
*
L01XE06
ATC
[U] dasatinib
+∞
24.5
23
*
L01EA02
ATC
dasatinib; oral
+∞
23.4
22
*
212
Kela drug reimbursment
Gout
22.1
22.7
33
18
127
Kela drug reimbursment
Transplant complication
68.6
21.4
24
*
324
Kela drug reimbursment
Dasatinib
+∞
19.1
18
*
L04AA01
ATC
[U] ciclosporin
174.4
15.7
16
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.7
14.8
25
42
A04AA01
ATC
ondansetron; systemic, rectal
16.5
14.0
22
15
D72.9
ICD-10 Finland
Disorder of white blood cells, unspecified
81.0
13.8
15
*
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
81.0
13.8
15
*
170
Kela drug reimbursment
Bosutinib
+∞
13.7
13
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
13.7
13
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.2
13.2
30
67
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.8
13.1
26
51
R50.9
ICD-10 Finland
Fever, unspecified
3.9
12.8
45
141
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
75.3
12.8
14
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
12.6
12
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.1
12.5
114
636
WW500
NOMESCO Finland
Blood transfusion
13.9
12.0
20
16
A03FA01
ATC
metoclopramide; systemic, rectal
3.8
11.9
42
132
JN4BD
NOMESCO Finland
Extensive body CT
5.9
10.7
20
37
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
116.4
10.5
11
*
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
+∞
10.5
10
*
115
Kela drug reimbursment
Breast cancer
+∞
10.5
10
*
360
Kela drug reimbursment
Bosutinib
+∞
10.5
10
*
L03AA04, ,
ATC
+∞
10.5
10
*
N02AA05
ATC
oxycodone; systemic
3.5
10.3
42
144
A01AB04
ATC
amphotericin B; local oral
5.6
10.1
20
39
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.9
9.9
33
99
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
105.3
9.5
10
*
L01EA04
ATC
bosutinib; oral
+∞
9.5
9
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
9.5
9
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
9.5
9
*
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
+∞
9.5
9
*
B03XA01
ATC
erythropoietin; parenteral
+∞
9.5
9
*
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
+∞
9.5
9
*
L03AB05
ATC
interferon alfa-2b; parenteral
+∞
9.5
9
*
Y84
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
38.8
9.1
11
*
C03CA01
ATC
furosemide; systemic
2.6
9.0
76
389
A05AA02
ATC
ursodeoxycholic acid; oral
15.0
8.8
14
10
WW200
NOMESCO Finland
Immunization
10.8
8.7
16
16
Z51.5
ICD-10 Finland
Palliative care
7.4
8.6
20
30
WZC00
NOMESCO Finland
Treatment plan or consultation
2.7
8.5
63
301
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
94.2
8.5
9
*
C95.9
ICD-10 Finland
Leukaemia, unspecified
+∞
8.4
8
*
121
Kela drug reimbursment
Severe hypofunction of sexual glands
12.6
7.7
13
11
B03XA02
ATC
darbepoetin alfa; parenteral
19.4
7.7
11
6
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
14.2
7.5
12
9
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
83.3
7.5
8
*
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
+∞
7.3
7
*
2051A
ICD-9 Finland
Myeloid leukaemia, Chronic
+∞
7.3
7
*
B73
ICPC
Leukaemia
+∞
7.3
7
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
7.3
7
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
7.3
7
*
J01MA14
ATC
moxifloxacin; systemic
3.6
7.3
26
81
B01AB10
ATC
tinzaparin; parenteral
3.7
6.7
22
65
H02AB04
ATC
methylprednisolone; systemic
2.8
6.5
36
146
R72
ICD-10 Finland
Abnormality of white blood cells, not elsewhere classified
72.3
6.5
7
*
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
72.3
6.5
7
*
L02AE02
ATC
leuprorelin; implant, parenteral
72.3
6.5
7
*
JN4AD
NOMESCO Finland
Body CT examination
3.8
6.4
20
57
Z3231
NOMESCO Finland
Registered nurse
2.4
6.4
57
293
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
6.3
6
*
373
Kela drug reimbursment
Ponatinib
+∞
6.3
6
*
116
Kela drug reimbursment
Prostate cancer
+∞
6.3
6
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
6.3
6
*
C90.0
ICD-10 Finland
Multiple myeloma
+∞
6.3
6
*
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
27.7
6.3
8
*
JN3AD
NOMESCO Finland
Abdominal CT examination
2.9
6.2
31
119
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.2
6.1
67
375
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
6.0
46
219

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
68
12
89.87
125.57
2.0
1.3
—
—
—
0
0
97
147
12.99
69.08
3.4
2.0
70.96
63.72
e9/l
0.90
67
107
132
476
7.45
37.27
23.1
5.5
—
—
—
0
0
151
701
7.78
29.81
25.0
5.4
54.85
57.96
%
2.97
151
667
58
117
6.81
29.62
10.7
4.2
3.64
0.74
%
3.71
43
33
114
424
5.52
29.02
7.4
2.5
336.76
362.87
umol/l
1.80
109
373
155
761
7.99
27.97
24.7
5.3
0.59
0.58
e9/l
0.07
148
649
155
766
7.90
27.61
24.6
5.3
0.11
0.04
e9/l
0.49
147
654
54
109
6.62
27.40
9.6
4.3
2.72
0.31
%
4.57
39
29
155
775
7.74
26.96
24.8
5.3
1.87
1.85
e9/l
0.09
147
682
49
92
6.92
26.66
1.5
1.5
—
—
—
0
0
155
789
7.50
25.98
26.7
5.4
0.26
0.19
e9/l
1.72
149
681
111
439
4.92
25.23
12.5
3.2
7.39
7.40
ph
1.14
92
297
156
831
7.14
23.83
32.2
6.5
4.85
4.36
e9/l
0.19
149
723
146
761
5.64
22.15
16.9
6.1
1.21
1.21
mmol/l
0.12
133
664
49
115
5.46
20.77
11.9
4.5
0.51
0.00
%
2.76
35
25
30
21
16.85
18.90
1.1
1.1
—
—
—
0
0
45
112
5.01
17.64
12.1
4.3
0.93
0.07
%
0.78
30
28
24
33
8.23
16.96
1.1
1.1
—
—
—
0
0
52
151
4.42
16.76
1.6
1.5
—
—
—
0
0
56
187
3.88
14.74
1.7
1.5
—
—
—
0
0
64
236
3.64
14.52
4.0
2.4
2.30
2.27
g/l
0.19
64
217
68
261
3.56
14.51
4.0
2.3
12.96
13.18
umol/l
0.10
68
241
119
668
3.26
13.11
32.1
9.8
0.03
0.00
e9/l
0.62
105
543
83
393
3.04
12.10
6.9
4.0
—
—
—
0
0
74
329
3.11
12.05
16.6
4.1
—
—
—
0
0
23
28
9.24
11.21
1.4
1.3
—
—
—
0
0
88
454
2.82
10.65
4.1
2.0
—
—
—
0
0
84
426
2.80
10.46
22.5
4.6
—
—
—
0
0
19
20
10.46
10.04
1.0
1.0
—
—
—
0
0
139
943
3.01
9.42
8.6
4.5
6.56
6.70
mmol/l
0.44
134
896
18
21
9.38
9.04
1.1
1.0
238.00
186.56
u/ml
—
13
9
14
10
15.04
8.85
1.0
1.2
—
—
—
0
0
12
7
18.21
8.19
1.2
1.7
2.54
2.83
mg/l
—
12
7
15
16
10.10
7.95
2.1
1.2
33.13
33.13
pg
0.00
15
16
18
27
7.27
7.81
1.1
1.0
—
—
—
0
0
62
309
2.53
7.56
1.5
1.3
2.00
2.80
g/l
3.80
50
171
50
226
2.67
7.43
1.8
1.8
—
—
—
0
0
14
16
9.37
7.19
1.6
1.7
—
—
—
0
0
14
16
9.37
7.19
1.6
1.7
—
—
—
0
0
14
16
9.37
7.19
1.6
1.7
—
—
—
0
0
14
16
9.37
7.19
1.6
1.7
—
—
—
0
0
31
110
3.19
7.11
1.5
1.3
—
—
—
0
0
110
730
2.28
6.75
12.0
13.3
1.20
1.27
inr
0.78
93
614
87
529
2.23
6.56
5.5
2.2
164.24
353.50
u/l
0.76
87
504
100
646
2.22
6.46
4.8
2.4
—
—
estimate
—
0
0
71
400
2.27
6.41
4.7
2.8
—
0.00
estimate
—
0
6
73
424
2.21
6.05
2.3
1.6
—
—
—
0
0
13
18
7.69
6.04
5.5
3.3
2.78
4.81
e9/l
1.99
13
18
15
29
5.54
5.53
5.4
2.4
50.67
61.62
%
1.66
15
29
10
11
9.54
5.36
1.1
1.0
—
—
—
0
0
55
299
2.20
5.27
4.8
2.0
2.45
2.44
mmol/l
0.10
55
261
5
0
+∞
5.23
1.0
0.0
—
—
—
0
0
5
0
+∞
5.23
1.0
0.0
—
—
—
0
0
11
16
7.24
5.03
2.2
1.2
1.03
0.78
%
—
6
10
60
344
2.11
4.99
2.0
1.7
1.22
1.10
mg/l
0.17
50
272
39
189
2.35
4.86
9.2
6.9
0.29
1.18
mmol/l
0.46
30
158
79
507
1.99
4.79
5.6
3.1
990.12
177.70
e6/l
0.39
68
381
10
14
7.48
4.72
4.9
4.4
—
—
—
0
0
70
433
2.00
4.69
5.1
2.9
0.46
0.33
e6/l
0.29
60
305
77
493
1.97
4.67
2.0
1.7
18.91
20.37
nmol/l
0.43
72
426
43
223
2.22
4.57
1.9
1.9
—
—
—
0
0
85
569
1.93
4.48
6.1
3.7
77.94
74.21
e6/l
0.03
73
395
28
121
2.55
4.45
1.5
1.1
—
—
—
0
0
15
38
4.21
4.42
3.5
2.8
4.22
1.80
index
—
9
20
46
251
2.11
4.28
5.2
2.9
2.55
3.17
e6/l
0.17
26
114
13
30
4.58
4.22
1.5
1.1
—
—
—
0
0
37
194
2.14
3.79
9.9
6.8
7.43
7.42
ph
0.38
22
113
18
68
2.83
3.69
2.3
2.0
166.81
1073.85
ug/l
0.75
18
62
7
9
8.03
3.59
1.3
2.1
0.79
0.67
e9/l
—
7
9
7
11
6.57
3.21
1.6
1.2
—
—
—
0
0
7
11
6.57
3.21
1.4
1.9
34.54
42.80
%
—
7
11
6
8
7.71
3.08
1.7
1.0
—
—
—
0
0
15
59
2.68
2.87
2.9
1.8
3.10
2.25
ug/l
0.12
15
52
21
98
2.29
2.84
5.8
4.4
—
—
—
0
0
5
6
8.52
2.76
1.6
1.7
—
—
—
0
0
5
6
8.52
2.76
1.0
1.2
—
—
—
0
0
10
29
3.59
2.73
1.0
1.3
—
—
—
0
0
6
10
6.16
2.72
1.7
1.5
—
—
—
0
0
5
7
7.30
2.56
2.8
2.0
1.20
0.86
index
—
5
7
94
739
1.56
2.30
2.8
2.1
90.15
97.57
pmol/l
0.82
65
373
36
225
1.75
2.18
1.4
1.4
333.33
486.32
titre
—
6
57
141
1227
1.66
2.15
57.8
17.2
14.66
13.54
%
14.32
141
1216
6
16
3.84
1.95
1.3
1.1
127.50
108.12
pmol/l
—
6
16
24
137
1.87
1.95
13.6
7.6
—
—
—
0
0
29
176
1.77
1.94
2.2
1.8
—
—
—
0
0
48
341
1.55
1.77
6.4
4.0
164.19
483.37
ng/l
1.06
42
272
9
36
2.58
1.76
1.2
1.1
—
—
—
0
0
5
13
3.92
1.72
2.8
2.2
11.80
12.29
index
—
5
7
12
55
2.27
1.71
1.3
1.3
—
—
—
0
0
99
825
1.44
1.62
4.4
3.9
0.00
0.03
estimate
0.50
16
155
10
43
2.40
1.61
3.9
1.8
—
—
—
0
0
57
429
1.48
1.59
4.5
3.2
—
—
—
0
0
6
20
3.07
1.59
1.3
2.2
-0.25
0.14
mmol/l
—
6
20
17
93
1.91
1.58
7.4
3.2
24.42
24.66
mmol/l
0.09
17
93
5
15
3.40
1.53
1.2
2.0
—
—
—
0
0
46
610
0.67
1.53
3.7
3.4
—
—
—
0
0
7
27
2.65
1.53
3.9
3.1
10.10
11.06
pmol/l
—
7
27
7
27
2.65
1.53
2.0
2.6
—
—
—
0
0
96
807
1.40
1.44
4.3
3.8
0.00
0.00
estimate
-0.00
17
161
97
817
1.40
1.44
4.3
3.8
0.00
0.00
estimate
-0.00
16
165
5
122
0.39
1.43
1.0
1.4
—
—
—
0
0
29
193
1.60
1.40
2.1
1.6
—
—
—
0
0
5
17
2.99
1.37
1.2
1.7
1271.00
638.82
mg
—
5
17
17
98
1.81
1.36
5.9
3.2
1.24
1.22
mmol/l
0.59
17
80
118
1034
1.40
1.35
5.9
4.3
—
3.91
—
0
5
57
443
1.42
1.33
2.9
3.2
—
0.20
—
0
10
15
84
1.86
1.31
2.9
2.2
—
—
—
0
0
10
49
2.10
1.24
1.0
1.1
—
—
—
0
0
8
37
2.21
1.23
1.5
2.1
—
5.29
—
0
18
5
19
2.68
1.22
2.2
2.0
9.40
10.68
mmol/l
—
5
19
14
80
1.81
1.16
5.1
3.9
—
—
—
0
0
52
408
1.38
1.13
1.4
1.3
—
—
—
0
0
5
21
2.42
1.10
2.2
1.8
2.36
178.51
u/ml
—
5
21
5
22
2.31
1.04
4.0
5.4
10.88
12.09
mg/l
—
5
22
23
157
1.53
1.02
1.3
1.3
—
—
—
0
0
19
124
1.59
1.01
3.7
3.0
—
—
—
0
0
77
654
1.31
0.98
3.1
3.5
6.34
6.16
ph
0.56
34
366
158
1488
1.47
0.96
41.5
14.1
18.37
24.32
mg/l
2.30
149
1193
6
27
2.26
0.94
2.0
1.2
—
—
—
0
0
15
96
1.61
0.87
1.7
1.7
—
—
—
0
0
148
1550
0.76
0.69
28.8
12.8
—
—
—
0
0
7
42
1.69
0.69
4.3
2.9
71.29
58.00
%
—
7
42
11
70
1.61
0.67
1.0
1.4
—
—
—
0
0
12
175
0.66
0.64
1.3
1.6
—
—
—
0
0
0
20
0.00
0.60
0.0
1.5
—
—
—
0
0
24
185
1.34
0.60
2.7
2.2
227.86
108.21
ug/g
0.92
17
149
0
23
0.00
0.58
0.0
2.5
—
105.13
—
0
23
0
23
0.00
0.58
0.0
2.2
—
1.06
—
0
14
0
23
0.00
0.58
0.0
2.5
—
1.20
—
0
23
0
23
0.00
0.58
0.0
2.5
—
4.15
—
0
23
45
382
1.24
0.55
5.0
3.9
1.02
1.02
kg/l
0.26
33
242
23
179
1.33
0.54
6.7
3.1
7.35
7.39
ph
0.95
15
106
142
1476
0.83
0.44
6.1
5.3
6.06
6.00
mmol/l
0.21
137
1356
0
15
0.00
0.41
0.0
2.9
—
—
—
0
0
19
151
1.29
0.40
2.1
1.5
—
—
—
0
0
72
658
1.16
0.39
4.1
3.8
22.94
45.26
ng/l
2.46
58
489
9
66
1.38
0.39
1.1
1.2
—
1.40
—
0
7
6
44
1.38
0.35
1.0
1.4
—
—
—
0
0
70
646
1.14
0.32
4.5
4.1
1.47
1.79
ug/l
0.88
63
578
6
47
1.29
0.32
1.3
1.2
—
—
—
0
0
50
452
1.15
0.31
5.1
3.6
0.00
0.00
estimate
-0.00
14
151
7
53
1.33
0.31
1.0
1.4
—
—
—
0
0
7
53
1.33
0.31
1.0
1.4
—
—
—
0
0
7
54
1.31
0.31
1.0
1.4
—
—
—
0
0
7
54
1.31
0.31
1.0
1.4
—
—
—
0
0
12
94
1.30
0.29
1.2
1.3
36.38
122.28
u/ml
—
5
33
41
369
1.14
0.27
2.3
2.7
0.63
0.75
ug/l
0.57
25
228
8
66
1.22
0.27
2.4
1.7
—
—
—
0
0
37
332
1.14
0.26
1.4
1.9
538.50
452.82
pmol/l
0.37
30
277
5
37
1.36
0.23
2.4
1.8
—
—
—
0
0
18
153
1.20
0.23
2.4
2.4
5.27
10.77
ug/l
1.55
18
135
149
1523
0.88
0.22
7.1
6.3
2.36
2.65
mmol/l
3.99
149
1418
62
580
1.10
0.22
3.9
3.5
8.06
7.98
mmol/l
0.05
52
490
10
80
1.26
0.21
1.2
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
6
51
1.18
0.19
1.0
1.5
—
—
—
0
0
61
574
1.09
0.19
4.5
4.4
12.77
8.22
mg/mmol
0.25
44
370
5
65
0.76
0.17
1.4
1.6
—
8.90
—
0
8
11
130
0.84
0.16
1.6
1.5
—
—
—
0
0
36
333
1.10
0.16
1.3
1.3
0.37
1.87
u/ml
—
7
92
6
80
0.74
0.16
1.2
1.1
—
—
—
0
0
24
221
1.10
0.11
1.2
1.3
—
—
—
0
0
11
96
1.16
0.10
2.9
3.6
1.01
1.02
ratio
0.78
11
90
12
106
1.14
0.10
5.0
3.3
—
—
—
0
0
5
48
1.04
0.09
2.2
1.5
—
—
—
0
0
6
55
1.09
0.09
1.0
1.1
—
—
—
0
0
29
274
1.07
0.08
1.3
1.3
1.05
14.95
u/ml
—
8
99
58
562
1.05
0.07
4.0
3.6
89.00
57.30
mg/l
0.29
45
371
12
109
1.11
0.06
1.2
1.2
—
—
—
0
0
11
120
0.91
0.05
4.3
2.6
113.82
130.83
g/l
1.74
11
115
58
569
1.03
0.03
3.0
3.6
—
—
—
0
0
44
448
0.98
0.01
4.3
3.4
0.00
0.00
estimate
-0.00
14
127
63
629
1.00
0.00
4.8
3.7
0.00
0.02
estimate
0.50
13
129
30
305
0.98
0.00
1.3
1.3
16.79
43.31
iu/ml
—
9
89
150
1498
1.01
0.00
6.3
5.5
4.23
4.54
mmol/l
3.51
150
1398
9
94
0.96
-0.00
4.6
2.4
0.54
0.61
%
—
9
94
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.2
—
6.92
—
0
5
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
1839.00
—
0
5
12
120
1.00
-0.00
1.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
1702.29
—
0
7
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
26.00
—
0
5
9
95
0.94
-0.00
4.6
2.4
1.28
1.27
%
—
9
95
0
5
0.00
-0.00
0.0
2.4
—
123.40
—
0
5
0
7
0.00
-0.00
0.0
11.9
—
0.66
—
0
7

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_CML – Chronic myeloid leukaemia

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).